The Centers for Medicare and Medicaid Services announced Aug. 28 it blocked more than $1.6 billion in potentially fraudulent Medicare payments to laboratory providers and revoked 157 fraudulent labs from the program, one of the largest single fraud prevention actions in the agency’s history.
The enforcement wave targets laboratory fraud, a persistent and high-dollar category of Medicare waste and abuse that has cost taxpayers billions of dollars over the past decade, CMS said. The agency described the outcome as a major anti-fraud milestone in its ongoing program integrity campaign.
Medicare serves more than 65 million Americans, and laboratory services are among the most frequently billed and most frequently fraudulently billed categories of covered benefits. Common laboratory fraud schemes include billing for tests never performed, billing for medically unnecessary tests and using fraudulent provider identities.
The $1.6 billion in blocked payments represents money that CMS intercepted before it left the Medicare trust funds, protecting the financial integrity of the program, the agency said. The revocation of 157 providers removes those entities from the Medicare billing system entirely.
For Medicare beneficiaries, fraudulent laboratory providers pose both financial and health risks. Patients may receive unnecessary blood draws or diagnostic tests, or may never receive tests that were billed on their behalf, potentially missing critical diagnoses.
The HHS Office of Inspector General works alongside CMS on program integrity investigations and has identified laboratory fraud as a top enforcement priority. The Government Accountability Office has also placed Medicare on its high-risk list for improper payments for more than two decades.
CMS did not identify specific labs or geographic concentrations targeted in the enforcement action.